Regeneron - Entering the Commercial TRAP

Name: Regeneron - Entering the Commercial TRAP
Brand: MP Advisors
SKU: R3C91772178EN
Price: 140.00 USD
Availability: InStock

July 2011 | 7 pages | ID: R3C91772178EN
MP Advisors

US$ 140.00

E-mail Delivery (PDF), Online Subscription, E-mail Delivery (Word)

Download PDF Leaflet

Wire Transfer

Checkout Later

Need Help? Ask a Question

Abstracts
Contents

Eylea (VEGF Trap-Eye, R, partnered with Bayer for Ex-US) for wet age-related macular degeneration (AMD) should win approval in the US next month (PDUFA: August, 20). What are the risks to its commercial success and future of REGN’s pipeline? A comprehensive analysis about the risk and the pipeline is included in this report. Purchase of this report will entitle the buyer to other relevant notes on REGN!!

COMPANIES MENTIONED

REGENERON

More Publications

REGENERON, Outperform - Is Trap Safer? Rilonacept vs. NVS’ Ilaris in Gout US$ 90.00 June 2011 5 pages

REGENERON: Tapping Other TRAPS in 3Q12 - ZALTRAP and ARCALYST! US$ 90.00 April 2012 5 pages

Hemophilia B - Pipeline Review, H2 2018 US$ 2,000.00 September 2018 135 pages

Regeneron - Entering the Commercial TRAP

More Publications

Need Help?

Ask a Question

Market Reports